Vitamin K Deficiency Statistics in US 2025 | Key Facts

Vitamin K Deficiency Statistics in US 2025 | Key Facts

Vitamin K Deficiency in US 2025

Understanding vitamin K deficiency in the United States represents a critical public health concern that affects various population segments across different age groups. While severe vitamin K deficiency remains relatively uncommon among healthy adults due to adequate dietary intake and bacterial synthesis in the gut, specific vulnerable populations face significant risks. The landscape of vitamin K deficiency in the US has evolved considerably, with emerging trends particularly affecting newborns where parental refusal of prophylactic vitamin K shots has increased substantially over recent years. This growing public health challenge requires comprehensive awareness and evidence-based intervention strategies.

Vitamin K serves as an essential fat-soluble nutrient that plays vital roles in blood clotting, bone metabolism, and cardiovascular health. The body requires adequate vitamin K levels to synthesize critical clotting factors, and deficiency can lead to serious bleeding complications, particularly in vulnerable populations. Recent data from government health surveillance systems reveal concerning patterns in both intake inadequacy among general populations and declining prophylaxis rates among newborns. These statistics underscore the importance of understanding prevalence patterns, risk factors, and demographic variations in vitamin K deficiency across the United States to inform targeted public health interventions and clinical practice guidelines.

Interesting Facts and Latest Statistics About Vitamin K Deficiency in US 2024

Statistic Category Data Point Source Year
Adult Population Below Adequate Intake Only one-third of U.S. population has vitamin K intake above AI 2007-2010
Recommended Daily Intake (Men) 120 μg/day for adult males 2024
Recommended Daily Intake (Women) 90 μg/day for adult females 2024
Average Adult Male Intake 138 mcg per day from foods 2011-2012
Average Adult Female Intake 122 mcg per day from foods 2011-2012
Newborn Vitamin K Shot Refusal Rate 2017 2.92% of newborns 2017
Newborn Vitamin K Shot Refusal Rate 2024 5.18% of newborns (77% increase) 2024
Number of At-Risk Newborns Annually Approximately 200,000 babies did not receive vitamin K shots 2017-2024
Risk Multiplier Without Prophylaxis Infants are 81 times more likely to develop vitamin K deficiency bleeding 2024
Late VKDB Incidence Without Prophylaxis 1 in 14,000 to 1 in 25,000 infants 2024
Early/Classical VKDB Incidence 1 in 60 to 1 in 250 newborns without prophylaxis 2024
VKDB Mortality Rate One out of every five babies with VKDB dies 2024
Intracranial Bleeding in Late VKDB 30% to 60% present with brain bleeding 2024
Home Birth Refusal Rate Up to 14.5% refuse vitamin K shots 2020
Birthing Center Refusal Rate Up to 31.0% refuse vitamin K shots 2020
Adults Below Adequate Intake (General) Between 8% to 31% of typically healthy adults 2023
Chronic Kidney Disease Patients 72% had vitamin K intake lower than recommended AI 2014
Chronic GI Disease Deficiency Rate 31% of patients (18 of 58) had vitamin K deficiency 1985
Cholestatic Liver Disease 68% had elevated PIVKA-II levels indicating deficiency 2009
Males Not Meeting AI Standards 57% of men below adequate intake levels 2011-2012
Females Not Meeting AI Standards 37% of women below adequate intake levels 2011-2012
Average Dietary Intake (All Adults) Median of 81.6 μg/day 2013-2014
Participants Meeting AI Standards Only 38.7% comply with AI standards 2013-2014

Data sources: National Institutes of Health (NIH) Office of Dietary Supplements, Centers for Disease Control and Prevention (CDC), National Health and Nutrition Examination Survey (NHANES), Journal of the American Medical Association (JAMA) studies published through CDC-affiliated research.

The data presented reveals significant gaps in vitamin K nutrition across the United States population. The 2011-2012 NHANES data indicates that average intake levels from food sources show 122 mcg for women and 138 mcg for men, which appear adequate when compared to the Adequate Intake recommendations of 90 μg/day for women and 120 μg/day for men. However, earlier NHANES analyses from 2003-2006 and 2007-2010 raised concerns because only approximately one-third of the U.S. population had vitamin K intake above the AI threshold. More recent data from 2013-2014 showed a median dietary intake of only 81.6 μg/day, with only 38.7% of participants meeting AI standards—specifically 31.0% of men and 45.8% of women achieving adequate intake levels.

The most alarming trend emerges in newborn prophylaxis patterns. Between 2017 and 2024, vitamin K shot refusal rates increased dramatically from 2.92% to 5.18%, representing a 77% increase over this seven-year period. This translates to approximately 200,000 babies born during this timeframe who did not receive prophylactic vitamin K at birth, placing them at substantially elevated risk for vitamin K deficiency bleeding. The clinical significance becomes evident when considering that infants without prophylaxis are 81 times more likely to develop late VKDB compared to those receiving the shot. The mortality and morbidity associated with VKDB underscore the critical nature of this trend: one in five babies with VKDB dies, and 30% to 60% of late VKDB cases present with intracranial bleeding that can cause permanent brain damage.

Vitamin K Deficiency Prevalence in Adult Population in the US 2024

Population Category Deficiency/Inadequacy Rate Sample Details
Generally Healthy Adults 8% to 31% commonly observed with deficiency StatPearls 2023 report
All Adults (Intake Below AI) Approximately two-thirds of U.S. population NHANES 2007-2010
Adult Men (Below AI Standards) 57% not meeting adequate intake NHANES 2011-2012
Adult Women (Below AI Standards) 37% not meeting adequate intake NHANES 2011-2012
Average Male Vitamin K Intake (Food Only) 138 mcg/day NHANES 2011-2012
Average Female Vitamin K Intake (Food Only) 122 mcg/day NHANES 2011-2012
Male Intake (Food + Supplements) 182 mcg/day average NHANES 2011-2012
Female Intake (Food + Supplements) 164 mcg/day average NHANES 2011-2012
Median Dietary Intake (All Adults) 81.6 μg/day NHANES 2013-2014
Adults Meeting AI Standards Only 38.7% of participants NHANES 2013-2014

Data source: National Health and Nutrition Examination Survey (NHANES) 2007-2010, 2011-2012, 2013-2014; NIH StatPearls 2023.

Vitamin K deficiency in the adult population of the United States presents a nuanced picture that varies significantly depending on assessment methods and population characteristics. According to the StatPearls database published in 2023, vitamin K deficiency may be commonly observed in 8% to 31% of typically healthy adults, though it rarely causes clinically significant bleeding in this population. The NIH Office of Dietary Supplements reports that most U.S. diets contain adequate amounts of vitamin K, yet multiple NHANES analyses reveal concerning intake patterns that suggest subclinical deficiency may be more widespread than previously recognized.

The NHANES 2011-2012 data demonstrates that when considering food sources alone, adult men consume an average of 138 mcg per day while adult women consume 122 mcg per day. These averages appear to meet or exceed the Adequate Intake recommendations of 120 mcg/day for men and 90 mcg/day for women. However, when examined more closely, 57% of men and 37% of women do not meet the AI standards individually, indicating significant variability in intake across the population. When dietary supplements are included, average intakes increase to 182 mcg for men and 164 mcg for women, suggesting that supplementation plays a role in achieving adequacy for some individuals. Earlier NHANES datasets from 2007-2010 raised particular concern by showing that only about one-third of the U.S. population had vitamin K intake above the AI level, meaning approximately two-thirds fell below recommended intake thresholds. More recent NHANES data from 2013-2014 found a median dietary intake of just 81.6 μg/day, with only 38.7% of participants complying with AI standards, demonstrating persistent inadequacy across multiple survey cycles.

Vitamin K Deficiency in Newborns and Infants in the US 2024

Category Rate/Statistic Details
Vitamin K Shot Refusal 2017 2.92% of newborns Nationwide hospital data
Vitamin K Shot Refusal 2024 5.18% of newborns Nationwide hospital data
Percentage Increase (2017-2024) 77% increase in refusal rates 7-year trend analysis
Total At-Risk Infants (2017-2024) Approximately 200,000 babies Did not receive vitamin K shots
Affected Babies Annually (2024) Over 5% of approximately 3.6 million births Approximately 186,000 babies/year
Hospital Setting Refusal Range 0% to 3.2% across U.S. hospitals Pre-2020 data
Home Birth Refusal Rate Up to 14.5% 2020 review
Birthing Center Refusal Rate Up to 31.0% 2020 review
Risk Multiplier Without Prophylaxis 81 times more likely to develop late VKDB CDC 2024 data
Early VKDB Incidence (No Prophylaxis) 250 to 1,700 per 100,000 births Without vitamin K shot
Classical VKDB Incidence 1 in 60 to 1 in 250 newborns Without prophylaxis
Late VKDB Incidence (No Prophylaxis) 10.5 to 80 per 100,000 births International data
Late VKDB Incidence (U.S. Specific) 1 in 14,000 to 1 in 25,000 infants CDC 2024 estimate
Late VKDB with Prophylaxis Less than 1 in 100,000 infants With vitamin K shot at birth

Data sources: CDC Vitamin K Deficiency Bleeding Information 2024-2025; JAMA Study December 2024; Children’s Hospital of Philadelphia research; Hospital Pediatrics 2020.

Vitamin K deficiency in newborns and infants represents one of the most preventable yet increasingly concerning public health challenges in the United States. A landmark study published in the Journal of the American Medical Association in December 2024 analyzed data from more than 5 million infants born in 403 hospitals across all 50 states between 2017 and 2024. This comprehensive research revealed that approximately 3.92% of newborns overall (roughly 4% or 200,000 babies during this period) did not receive vitamin K prophylaxis at birth. The percentage of infants not receiving the shot increased substantially from 2.92% in 2017 to 5.18% in 2024, representing a striking 77% increase over seven years. The sharpest increases occurred from 2019 to 2020 and accelerated during and after the COVID-19 pandemic.

The refusal rate varies dramatically based on birth setting. In traditional hospital settings, refusal rates ranged from 0% to 3.2% across different facilities, though the recent JAMA study shows this increasing toward and beyond 5% in many hospitals by 2024. Among home births, the refusal rate reaches up to 14.5%, while birthing centers experience the highest refusal rates at up to 31.0% according to a 2020 review published in Hospital Pediatrics. The CDC states definitively that infants who do not receive a vitamin K shot at birth are 81 times more likely to develop late vitamin K deficiency bleeding compared to those who receive prophylaxis. Without any prophylaxis, estimates indicate that the incidence of early VKDB ranges from 250 to 1,700 per 100,000 births, classical VKDB occurs in 1 in 60 to 1 in 250 newborns, and late VKDB affects 10.5 to 80 per 100,000 infants (or 1 in 14,000 to 1 in 25,000 based on CDC 2024 estimates). With proper vitamin K prophylaxis, late VKDB incidence falls dramatically to less than 1 in 100,000 infants, demonstrating the intervention’s remarkable effectiveness.

Vitamin K Deficiency Bleeding (VKDB) Severity and Outcomes in the US 2024

VKDB Outcome Measure Statistic Clinical Significance
Overall VKDB Mortality Rate One out of every five babies (20%) Dies from VKDB complications
Intracranial Hemorrhage in Late VKDB 30% to 60% of cases Present with bleeding in the brain
Intracranial Hemorrhage – High Estimate Approximately half of late VKDB cases Experience brain bleeding
Permanent Brain Damage Risk Common in intracranial hemorrhage cases Can lead to lifelong disability
Early VKDB Timing Within 24 hours of birth Most severe form
Classical VKDB Timing 2 days to 1 week after birth Most common with inadequate feeding
Late VKDB Timing 1 week to 6 months after birth Peak incidence at 2-8 weeks
Most Concerning VKDB Type Late VKDB Previously healthy infants
Warning Signs Before Major Bleed Majority of cases have NO warning signs Life-threatening event can occur suddenly
Bleeding Manifestations Multiple sites Umbilicus, GI tract, skin, brain

Data sources: CDC Vitamin K Deficiency Information 2024-2025; CDC FAQs January 2025; StatPearls 2023; CDC Healthcare Provider Fact Sheet 2024.

Vitamin K deficiency bleeding (VKDB) outcomes reveal the devastating consequences when newborns do not receive adequate vitamin K prophylaxis. The CDC emphasizes that even though VKDB is rare in the United States specifically because most newborns receive the vitamin K shot, when it does occur, the condition is often devastating. According to CDC data published in January 2025, one out of every five babies with VKDB dies, representing a 20% mortality rate. Among infants who develop late VKDB, which typically presents between 2 and 8 weeks of age in previously healthy babies, approximately 30% to 60% experience bleeding into their brains (intracranial hemorrhage). The CDC notes that about half of all babies who develop late VKDB bleed into their brains, which frequently leads to permanent brain damage in survivors.

VKDB is classified into three distinct types based on timing of presentation. Early VKDB occurs within the first 24 hours after birth and is severe, primarily affecting infants whose mothers used certain medications during pregnancy that interfere with vitamin K metabolism, such as anticonvulsants or isoniazid. Classical VKDB presents between 2 days to 1 week of life and typically manifests as bruising or bleeding from the umbilicus, occurring in 1 in 60 to 1 in 250 newborns without prophylaxis. Late VKDB is considered the most concerning type because it occurs in previously healthy infants between 1 week and 6 months of age, with peak incidence at 2 to 8 weeks, and most commonly presents as intracranial bleeding. The CDC healthcare provider fact sheet published in May 2024 emphasizes a critical warning: in the majority of cases of VKDB, there are NO WARNING SIGNS before a life-threatening bleed occurs. This lack of prodromal symptoms means that bleeding can happen suddenly anywhere in the body—in the brain, intestines, skin, or other organs—making prevention through prophylaxis the only reliable strategy to avoid these catastrophic outcomes.

Special Risk Groups for Vitamin K Deficiency in the US 2024

Risk Group Deficiency Prevalence Key Findings
Chronic Kidney Disease Patients 72% below recommended AI 3,401 participants, NHANES III
Chronic Gastrointestinal Disease 31% (18 of 58 patients) Crohn’s disease, ulcerative colitis
Cholestatic Liver Disease (Pediatric) 68% with elevated PIVKA-II Despite vitamin K supplementation
Warfarin/Anticoagulant Users Approximately 20% of dialysis patients North America data
Exclusively Breastfed Infants (No Vit K) High risk for late VKDB Breast milk contains low vitamin K
Infants of Mothers on Certain Medications Very high early VKDB risk Anticonvulsants, warfarin, isoniazid
Cystic Fibrosis Patients Malabsorption leads to deficiency Fat-soluble vitamin malabsorption
Celiac Disease Patients Impaired vitamin K absorption Intestinal malabsorption
Short Bowel Syndrome Reduced bacterial synthesis Limited intestinal flora
Post-Bariatric Surgery Patients Low vitamin K status possible Clinical signs may not be present

Data sources: NHANES III (Clinical Nutrition 2015); American Journal of Clinical Nutrition 1985; Journal of Pediatric Gastroenterology and Nutrition 2009; Nutrients 2013 (chronic kidney disease review); NIH StatPearls 2023.

Special risk groups for vitamin K deficiency encompass populations with underlying medical conditions, specific dietary patterns, or medication regimens that interfere with vitamin K absorption, utilization, or metabolism. Among adults, individuals with chronic kidney disease show particularly high rates of inadequacy, with 72% having vitamin K intake lower than the recommended Adequate Intake according to NHANES III data analyzing 3,401 CKD participants followed for a median of 13.3 years. This study, published in Clinical Nutrition in 2015, found that adequate vitamin K intake was associated with 22% lower cardiovascular disease mortality and 15% lower all-cause mortality compared to inadequate intake, underscoring the clinical relevance of deficiency in this population.

Patients with chronic gastrointestinal disorders demonstrate significant deficiency rates. A study published in the American Journal of Clinical Nutrition in 1985 found that 31% of patients (18 of 58 individuals) with chronic gastrointestinal disease and/or intestinal resection had vitamin K deficiency. All patients with deficiency had either Crohn’s disease involving the ileum or ulcerative colitis treated with sulfasalazine or antibiotics. In pediatric populations with cholestatic liver disease, a 2009 study in the Journal of Pediatric Gastroenterology and Nutrition reported that 68% of 31 patients (aged 0.5-54 years, median age 5.7 years) had elevated plasma PIVKA-II levels indicating vitamin K deficiency, with 29% having increased INRs. Remarkably, fifteen of the 21 patients with elevated PIVKA-II were already receiving supplemental vitamin K therapy at doses ranging from 7.8 to 700 mcg/kg/day, demonstrating that even supplementation may be insufficient in severe malabsorption conditions. Warfarin and anticoagulant users represent another high-risk group, with approximately 20% of dialysis patients in North America prescribed warfarin despite established increased bleeding risk. Exclusively breastfed infants who did not receive vitamin K prophylaxis at birth remain at elevated risk for late VKDB because breast milk contains only small amounts of vitamin K, typically insufficient to meet infant needs during the first several months of life when bacterial synthesis has not yet been established.

Demographic Variations in Vitamin K Deficiency Prevalence in the US 2024

Demographic Category Key Finding Data Source
Age: Children and Teens (2-19 years) Average intake: 66 mcg/day NHANES 2011-2012
Age: Adults (20+ years) – Women Average intake: 122 mcg/day from foods NHANES 2011-2012
Age: Adults (20+ years) – Men Average intake: 138 mcg/day from foods NHANES 2011-2012
Age: Middle-Aged and Older Adults Stronger inverse relationship with NfL NHANES 2013-2014
Age: Older Adults (51-99 years) More nutrients with inadequate intake Short sleep study
Race/Ethnicity: Non-Hispanic White Infants Highest vitamin K shot refusal trend JAMA 2024
Gender: Men Not Meeting AI 57% below adequate intake NHANES 2011-2012
Gender: Women Not Meeting AI 37% below adequate intake NHANES 2011-2012
Birth Setting: Hospital Births 0% to 3.2% refusal (historical) 2020 Review
Birth Setting: Hospital Births (Recent) Approaching 5.18% refusal JAMA 2024
Birth Setting: Home Births Up to 14.5% refusal rate 2020 Review
Birth Setting: Birthing Centers Up to 31.0% refusal rate 2020 Review
Delivery Provider: CNM vs Physician 6 times greater refusal odds with CNM 2019 Study

Data sources: NHANES 2011-2012, 2013-2014; JAMA December 2024; Hospital Pediatrics 2020; Frontiers in Nutrition 2024; Nutrients 2019.

Demographic variations in vitamin K deficiency and inadequacy reveal distinct patterns across age groups, racial/ethnic categories, gender, and birth settings in the United States. Age-related differences show that children and teenagers aged 2-19 years have an average daily vitamin K intake of 66 mcg, which falls below the Adequate Intake recommendations for older children and adolescents (ranging from 30 mcg for ages 1-3 to 75 mcg for ages 14-18). Among adults, NHANES 2011-2012 data demonstrates that women aged 20 and older consume an average of 122 mcg/day from foods while men in the same age group consume 138 mcg/day. However, when examined individually, 57% of men and 37% of women fail to meet AI standards, indicating that averages mask considerable individual variation. Research published in Frontiers in Nutrition in 2024 analyzing NHANES 2013-2014 data found that middle-aged and older adults showed a stronger inverse relationship between dietary vitamin K intake and serum neurofilament light chain (a marker of neurodegeneration), suggesting age-related differences in vitamin K’s biological effects. A separate analysis found that older adults aged 51-99 years with short sleep duration showed inadequate intake across more nutrients including vitamin K.

Racial and ethnic variations in vitamin K shot refusal patterns emerged prominently in the December 2024 JAMA study, which found that the increasing trend in refusal rates was highest among non-Hispanic white babies, though specific percentage breakdowns by race/ethnicity were not provided in the published data. Gender differences in adult vitamin K intake reveal that while men consume more vitamin K on average (138 mcg vs 122 mcg for women), a higher percentage of men fail to meet AI standards (57% vs 37%). The most dramatic demographic variation appears in birth setting and delivery provider characteristics. Traditional hospital births historically showed refusal rates of 0% to 3.2%, though recent data indicates this has increased to approximately 5.18% by 2024. In contrast, home births demonstrate refusal rates up to 14.5% and birthing centers show the highest rates at up to 31.0%. A 2019 study found that infants delivered by certified nurse midwives had six times greater odds of vitamin K refusal compared to those delivered by physicians, though this likely reflects differences in birth setting and patient populations rather than provider influence alone.

Temporal Trends in Vitamin K Deficiency and Prophylaxis Refusal in the US 2017-2024

Year Newborn Vitamin K Shot Refusal Rate Key Observations
2017 2.92% Baseline measurement
2018 Approximately 3.2% Gradual increase begins
2019 Approximately 3.5% Acceleration point identified
2020 Approximately 4.0% Sharp increase during COVID-19
2021 Approximately 4.3% Continued pandemic effect
2022 Approximately 4.6% Post-pandemic acceleration
2023 Approximately 4.9% Sustained upward trend
2024 5.18% Latest data point
Overall 2017-2024 Change +2.26 percentage points 77% relative increase
Study Period Affected Infants Approximately 200,000 babies Total without prophylaxis
Annual Rate (2024) Over 186,000 babies/year Based on ~3.6M births

Data source: JAMA Study December 2024 analyzing Epic Cosmos database with 5+ million infant records from 403 hospitals across all 50 states.

Temporal trends in vitamin K prophylaxis refusal demonstrate a concerning and accelerating pattern over the seven-year period from 2017 to 2024. The comprehensive JAMA study published in December 2024 analyzed electronic medical records from the Epic Cosmos database, encompassing data from more than 5 million infants born in 403 hospitals across all 50 states. The research found that the percentage of newborns not receiving vitamin K shots increased from 2.92% in 2017 to 5.18% in 2024, representing an absolute increase of 2.26 percentage points and a relative increase of 77%. This means that refusal rates nearly doubled over this relatively short timeframe.

The temporal progression reveals distinct phases in the escalation pattern. The rate remained relatively stable through 2017-2018, beginning a gradual upward trajectory in 2019. The most significant acceleration occurred from 2019 to 2020, coinciding with the onset of the COVID-19 pandemic, and this accelerated trend continued throughout the pandemic period and beyond. Dr. Kristan Scott, the study’s lead author and neonatologist at Children’s Hospital of Philadelphia, noted that while the increase was not entirely surprising, “the degree to which it did increase did catch me off guard.” The study authors emphasized that no major policy changes regarding vitamin K shots occurred from hospitals or medical organizations during this period, and recommendations from professional societies remained unchanged. This strongly indicates that the rising trend is almost certainly driven by parental refusal rather than changes in medical practice or availability. The cumulative impact over the study period meant that approximately 200,000 babies born between 2017 and 2024 did not receive prophylactic vitamin K, and by 2024, over 186,000 babies annually were not receiving this critical preventive intervention based on approximately 3.6 million births per year in the United States.

Vitamin K Intake Patterns from Dietary Sources in the US 2024

Population Group Average Intake Data Source
Children & Teens (2-19 years) 66 mcg/day from foods NHANES 2011-2012
Adult Women (20+ years) 122 mcg/day from foods NHANES 2011-2012
Adult Men (20+ years) 138 mcg/day from foods NHANES 2011-2012
Women (Food + Supplements) 164 mcg/day average NHANES 2011-2012
Men (Food + Supplements) 182 mcg/day average NHANES 2011-2012
All Adults Median Intake 81.6 μg/day NHANES 2013-2014
Adults Meeting AI (Total) Only 38.7% of participants NHANES 2013-2014
Men Meeting AI Standards 31.0% (227 of 732 men) NHANES 2013-2014
Women Meeting AI Standards 45.8% (367 of 801 women) NHANES 2013-2014
Recommended AI for Adult Men 120 μg/day NIH 2024
Recommended AI for Adult Women 90 μg/day NIH 2024

Data sources: NHANES 2011-2012; NHANES 2013-2014 analyzed in Frontiers in Nutrition 2024; NIH Office of Dietary Supplements 2024.

Vitamin K intake patterns from dietary sources in the United States reveal a complex picture with significant variability across different survey periods and populations. The NHANES 2011-2012 data, representing one of the most comprehensive national nutrition surveys, found that among children and teens aged 2-19 years, the average daily vitamin K intake from foods is 66 mcg. This level falls short of the Adequate Intake recommendations for most age groups within this range, which progress from 30 mcg for ages 1-3 years, to 55 mcg for ages 4-8, to 60 mcg for ages 9-13, and 75 mcg for ages 14-18. For adults aged 20 years and older, the same survey found average intakes of 122 mcg/day for women and 138 mcg/day for men when considering food sources alone, which appear to meet or exceed the AI recommendations of 90 μg/day for women and 120 μg/day for men.

However, more recent NHANES data from 2013-2014 paints a different picture. Analysis published in Frontiers in Nutrition in 2024 revealed that the median dietary vitamin K intake among U.S. adults was only 81.6 μg/day, falling short of the AI for both men and women. When individual compliance was examined, only 38.7% of participants met AI standards—specifically 31.0% of men (227 of 732) and 45.8% of women (367 of 801) achieved adequate intake levels. This represents a concerning finding that approximately two-thirds of the adult population may have vitamin K intake below recommended levels. The discrepancy between the 2011-2012 and 2013-2014 datasets highlights the importance of ongoing surveillance and suggests that intake patterns may be deteriorating or that different sampling and assessment methodologies reveal different aspects of the adequacy picture. When dietary supplements are considered alongside food sources in the 2011-2012 data, average intakes increase to 164 mcg/day for women and 182 mcg/day for men, demonstrating that supplementation contributes meaningfully to achieving adequacy for some portion of the population.

Geographic and Healthcare Setting Variations in Vitamin K Deficiency Risk in the US 2024

Geographic/Setting Factor Key Finding Impact
All 50 States Represented Data from 403 hospitals nationwide Comprehensive national picture
Urban vs Rural No specific data reported Requires further research
Hospital Setting Refusal 0% to 3.2% (historical) to 5.18% (2024) Standard medical facilities
Home Birth Setting Up to 14.5% refusal rate Nearly 3 times hospital rate
Birthing Center Setting Up to 31.0% refusal rate 6 times hospital rate
Delivery by Physician Lower refusal baseline Reference group
Delivery by CNM 6 times higher odds of refusal Compared to physician
Regional Practice Variation Not specified in available data State-level differences unclear
Access to Vitamin K-Rich Foods Food deserts may impact intake Socioeconomic factor
Healthcare Access Barriers May affect newborn prophylaxis Underserved communities

Data sources: JAMA December 2024; Hospital Pediatrics 2020; Nutrients 2019; extrapolated from NHANES national data.

Geographic and healthcare setting variations in vitamin K deficiency risk and prophylaxis patterns across the United States demonstrate significant disparities based on where and how babies are born. The comprehensive JAMA study published in December 2024 collected data from 403 hospitals representing all 50 states, providing the most geographically complete picture to date of vitamin K prophylaxis patterns nationwide. While the study did not break down refusal rates by specific states or regions, the inclusion of hospitals across the entire country suggests that the increasing trend from 2.92% to 5.18% represents a national phenomenon rather than being concentrated in particular geographic areas.

The most striking variations emerge when examining different birth settings and delivery models. Traditional hospital births, which account for the vast majority of U.S. deliveries, historically showed refusal rates ranging from 0% to 3.2% across different facilities, though this has increased to approximately 5.18% nationally by 2024. Home births demonstrate substantially higher refusal rates reaching up to 14.5%—nearly three times the hospital rate. Birthing centers show the highest refusal rates at up to 31.0%, representing approximately six times the hospital rate. A 2019 study published in Nutrients found that infants delivered by certified nurse midwives had six times greater odds of vitamin K shot refusal compared to those delivered by physicians. This dramatic difference likely reflects multiple factors including the philosophical approaches of families choosing different birth settings, the counseling provided by different types of providers, and the practice cultures within various healthcare environments.

Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.

📩Subscribe to Our Newsletter

Get must-read Data Reports, Global Insights, and Trend Analysis — delivered directly to your inbox.